Molecular cell biology of androgen receptor signalling

被引:209
作者
Bennett, Nigel C. [1 ,2 ]
Gardiner, Robert A. [2 ,3 ]
Hooper, John D. [4 ]
Johnson, David W. [5 ]
Gobe, Glenda C. [1 ]
机构
[1] Univ Queensland, Sch Med, Princess Alexandra Hosp, Discipline Med, Brisbane, Qld 4102, Australia
[2] Univ Queensland, Royal Brisbane & Womens Hosp, Clin Res Ctr, Brisbane, Qld 4102, Australia
[3] Royal Brisbane & Womens Hosp, Dept Urol, Brisbane, Qld, Australia
[4] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Brisbane, Qld 4001, Australia
[5] Princess Alexandra Hosp, Dept Renal Med, Brisbane, Qld 4102, Australia
关键词
Androgen receptor; Steroid hormones; Co-regulators; Prostate cancer; Genomic; Steroidogenesis; HUMAN PROSTATE-CANCER; N-TERMINAL DOMAIN; LIGAND-BINDING DOMAIN; DNA-BINDING; GROWTH-FACTOR; STRUCTURAL BASIS; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; INDEPENDENT ACTIVATION; NUCLEAR TRANSLOCATION;
D O I
10.1016/j.biocel.2009.11.013
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The classical action of androgen receptor (AR) is to regulate gene transcriptional processes via AR nuclear translocation. response element binding and recruitment of, or crosstalk with, transcription factors AR also utilises non-classical, non-genomic mechanisms of signal transduction These precede gene transcription or protein synthesis, and involve steroid-Induced modulation of cytoplasmic or cell membrane-bound regulatory proteins Despite many decades of investigation, the role of AR in gene regulation of cells and tissues remains only partially characterised AR exerts most of its effects in sex hormone-dependent tissues of the body, but the receptor is also expressed in many tissues not previously thought to be androgen sensitive. Thus it is likely that a complex, more over-arching, role for AR exists Each AR domain co-ordinates a multitude of individual and vital roles via a diverse array of interacting partner molecules that are necessary for cellular and tissue development and maintenance Aberrant AR activity, promoted by mutations or binding partner misregulation, can present as many clinical manifestations including androgen insensitivity syndrome and prostate cancer In the case of malignant prostate cancer, treatment generally revolves around androgen deprivation therapies designed to interfere with AR action and the androgen signalling axis Androgen therapies for prostate cancer often fail, highlighting a real need for increased research Into AR function. (C) 2009 Elsevier Ltd All rights reserved
引用
收藏
页码:813 / 827
页数:15
相关论文
共 174 条
[1]   Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven [J].
Attard, Gerhardt ;
Reid, Alison H. M. ;
Yap, Timothy A. ;
Raynaud, Florence ;
Dowsett, Mitch ;
Settatree, Sarah ;
Barrett, Mary ;
Parker, Christopher ;
Martins, Vanessa ;
Folkerd, Elizabeth ;
Clark, Jeremy ;
Cooper, Colin S. ;
Kaye, Stan B. ;
Dearnaley, David ;
Lee, Gloria ;
de Bono, Johann S. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4563-4571
[2]   Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer [J].
Attard, Gerhardt ;
Reid, Alison H. M. ;
A'Hern, Roger ;
Parker, Christopher ;
Oommen, Nikhil Babu ;
Folkerd, Elizabeth ;
Messiou, Christina ;
Molife, L. Rhoda ;
Maier, Gal ;
Thompson, Emilda ;
Olmos, David ;
Sinha, Rajesh ;
Lee, Gloria ;
Dowsett, Mitch ;
Kaye, Stan B. ;
Dearnaley, David ;
Kheoh, Thian ;
Molina, Arturo ;
de Bono, Johann S. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (23) :3742-3748
[3]   Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells [J].
Baron, S ;
Manin, M ;
Beaudoin, C ;
Leotoing, L ;
Communal, Y ;
Veyssiere, G ;
Morel, L .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (15) :14579-14586
[4]  
Bennett N, 2009, IUBMB LIFE, V61, P961, DOI [10.1002/IUB.244, 10.1002/iub.244]
[5]   Forskolin-induced dephosphorylation of the androgen receptor impairs ligand binding [J].
Blok, LJ ;
de Ruiter, PE ;
Brinkmann, AO .
BIOCHEMISTRY, 1998, 37 (11) :3850-3857
[6]   The androgen receptor associates with the epidermal growth factor receptor in androgen-sensitive prostate cancer cells [J].
Bonaccorsi, L ;
Muratori, M ;
Carloni, V ;
Marchiani, S ;
Formigli, L ;
Forti, G ;
Baldi, E .
STEROIDS, 2004, 69 (8-9) :549-552
[7]   Testosterone replacement therapy and prostate cancer: A word of caution [J].
Brand T.C. ;
Canby-Hagino E. ;
Thompson I.M. .
Current Urology Reports, 2007, 8 (3) :185-189
[8]   Molecular basis of androgen insensitivity [J].
Brinkmann, AO .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2001, 179 (1-2) :105-109
[9]   Androgen receptor corepressors and prostate cancer [J].
Burd, Craig J. ;
Morey, Lisa M. ;
Knudsen, Karen E. .
ENDOCRINE-RELATED CANCER, 2006, 13 (04) :979-994
[10]   Interplay between two hormone-independent activation domains in the androgen receptor [J].
Callewaert, L ;
Van Tilborgh, N ;
Claessens, F .
CANCER RESEARCH, 2006, 66 (01) :543-553